<SEC-DOCUMENT>0001213900-25-085909.txt : 20250909
<SEC-HEADER>0001213900-25-085909.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20250909104220
ACCESSION NUMBER:		0001213900-25-085909
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250909
FILED AS OF DATE:		20250909
DATE AS OF CHANGE:		20250909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		251302085

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0256606-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp; <B>001-38723</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;&#9746;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 9, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued this 6K announcing that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price
of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: September 9, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea025660601ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated September 9, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025660601ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED SEPTEMBER 9, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tiziana Life Sciences Announces Purchase of
Shares by Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOSTON, MA, September 9, 2025</B> &ndash; Tiziana Life Sciences,
Ltd. (Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation
therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that
its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open
market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological
drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November
of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative
human diseases.<SUP>1,2</SUP></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical
development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology
for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline
applications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana Life Sciences and its innovative
pipeline of therapies, please visit www.tizianalifesciences.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further inquiries:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# 28# 2(  A$! Q$!_\0
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M>_M+Q/J6I:/):Z7I]U8^$+Z%HF\86-A9Z?J"75Q:2M-<Z/=7#>I:I_P<Q?\
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MAPCPW5J2C#+\MK5:F8XS#\TE'^TLVE&C5DJD+.IAL#2P>&M)P<JT$^?]I/\
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M21\D_M^VEW?_ +"/[:MC86MS?7U[^R5^T;:6=E9P2W5W>75Q\'O&,-O:VMM
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M!GA1_%\8VQ^*F\.Z0WB2,>48,)KILSJBCR28?ENA^Z)C^Z2*ZS_/Y4 ?Y/\
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M4_#3QGI5PMWIOBOP#X0\16-RAW+/:ZQX?T^_ADW=\I.,]><\U_*O_P %:_\
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M"RGPY^(GQ8_X*N_\$6? 7PJ^-?B?]G?QSK2_MDMI/Q>\'>'O#WBGQ%X7BL?
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M_$[XG>./&D-MIMIJ.L30PZ7H6OZ[?>'=&E+L?/O-(TFQO;M D5U<31(B*44
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M3?BMX_\ B'8:5>S^,)89[S3+/QCXBUJVT^[FA40RW5G%#/)"/*>1H_EK]?\
M_@N#H:W'[$>N>-K'7O'7A7QA\*O$^G^/_ /B;X?_ !'^('PUUO0?%FGZ=JEA
M::E_:7P_\3>&KK5(HK74;R/^RM9DU'1Y&E$TNGO/%#)&44 ?E;_P;L_"#P%^
MU'X?^-7[7O[3.FZM^T1^TC<'3O@\GQ5^.?B_QC\6=;T_X:07@\0+X1T2Q\>Z
A_K^@^'].DUG3-/U"Y?0](T^\O)[2'[7=3HFRBBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
